Advisory Alpha LLC Has $734,000 Stake in Vertex Pharmaceuticals Incorporated $VRTX

Advisory Alpha LLC grew its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 17.2% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,514 shares of the pharmaceutical company’s stock after buying an additional 222 shares during the period. Advisory Alpha LLC’s holdings in Vertex Pharmaceuticals were worth $734,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in VRTX. Aries Wealth Management acquired a new stake in Vertex Pharmaceuticals during the 1st quarter worth approximately $293,000. Polar Asset Management Partners Inc. acquired a new stake in Vertex Pharmaceuticals during the 4th quarter worth approximately $22,954,000. Brighton Jones LLC lifted its holdings in Vertex Pharmaceuticals by 45.0% during the 1st quarter. Brighton Jones LLC now owns 6,421 shares of the pharmaceutical company’s stock worth $3,113,000 after purchasing an additional 1,994 shares during the last quarter. GAMMA Investing LLC lifted its holdings in Vertex Pharmaceuticals by 25.1% during the 1st quarter. GAMMA Investing LLC now owns 5,002 shares of the pharmaceutical company’s stock worth $2,425,000 after purchasing an additional 1,005 shares during the last quarter. Finally, Stanley Laman Group Ltd. acquired a new stake in Vertex Pharmaceuticals during the 1st quarter worth approximately $486,000. 90.96% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Bruce I. Sachs bought 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 6th. The stock was acquired at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the transaction, the director directly owned 45,000 shares of the company’s stock, valued at approximately $17,535,600. This represents a 12.50% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the company. Scotiabank dropped their price target on Vertex Pharmaceuticals from $442.00 to $438.00 and set a “sector perform” rating for the company in a report on Tuesday, August 5th. Guggenheim lowered their price objective on Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating on the stock in a research note on Wednesday, August 6th. BMO Capital Markets set a $530.00 price objective on Vertex Pharmaceuticals and gave the stock an “outperform” rating in a research note on Tuesday, August 5th. JPMorgan Chase & Co. raised their price objective on Vertex Pharmaceuticals from $515.00 to $517.00 and gave the stock an “overweight” rating in a research note on Monday, July 14th. Finally, Wall Street Zen lowered Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Friday, August 22nd. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and thirteen have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $497.10.

Vertex Pharmaceuticals Stock Up 0.3%

NASDAQ VRTX opened at $396.48 on Wednesday. Vertex Pharmaceuticals Incorporated has a twelve month low of $362.50 and a twelve month high of $519.88. The company has a market cap of $101.65 billion, a price-to-earnings ratio of 28.34 and a beta of 0.44. The business’s fifty day moving average is $426.38 and its 200 day moving average is $455.19.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, topping the consensus estimate of $4.24 by $0.28. The firm had revenue of $2.94 billion for the quarter, compared to the consensus estimate of $2.90 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The business’s quarterly revenue was up 11.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($12.83) EPS. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. On average, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.